← Back to Clinical Trials
Recruiting NCT06089902

NCT06089902 European Prospective Registry on Anomalous Aortic Origin of the Coronary Arteries

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06089902
Status Recruiting
Phase
Sponsor University of Padova
Condition Congenital Heart Disease
Study Type OBSERVATIONAL
Enrollment 500 participants
Start Date 2019-01-01
Primary Completion 2025-01-01

Eligibility & Interventions

Sex All sexes
Min Age N/A
Max Age N/A
Study Type OBSERVATIONAL
Interventions
unroofing or other surgery if needed

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 500 participants in total. It began in 2019-01-01 with a primary completion date of 2025-01-01.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Anomalous aortic origin of a coronary artery (AAOCA) is a group of rare congenital heart defects with various clinical presentations. The lifetime-risk of an individual living with AAOCA is unknown, and data from multicentre registries are urgently needed to adapt current recommendations and guide optimal patient management. The European Registry for AAOCA (EURO-AAOCA) aims to assess differences with regard to AAOCA management between centres.

Eligibility Criteria

Inclusion Criteria: * All patients with a diagnosis of AAOCA (either referred to surgery or to medical follow-up ) Exclusion Criteria: * isolated high-coronary take-off (≥ 5mm above sino-tubular junction), anomalous origin of a circumflex from the right coronary artery, anomalous course with a normal origin, and association to major congenital heart disease (i.e. Tetralogy of Fallot, transposition of the great arteries, anomalous origin of a coronary from the pulmonary artery).

Contact & Investigator

Central Contact

Massimo Padalino, MD PhD

✉ massimo.padalino@unipd.it

📞 00393408922564

Principal Investigator

Massimo Padalino, MD PhD

PRINCIPAL INVESTIGATOR

University of Padova

Frequently Asked Questions

Who can join the NCT06089902 clinical trial?

This trial is open to participants of all sexes, studying Congenital Heart Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06089902 currently recruiting?

Yes, NCT06089902 is actively recruiting participants. Contact the research team at massimo.padalino@unipd.it for enrollment information.

Where is the NCT06089902 trial being conducted?

This trial is being conducted at Padova, Italy, Bern, Switzerland.

Who is sponsoring the NCT06089902 clinical trial?

NCT06089902 is sponsored by University of Padova. The principal investigator is Massimo Padalino, MD PhD at University of Padova. The trial plans to enroll 500 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology